Detection of High-Risk Human Papillomavirus DNA in Invasive Ductal Carcinoma Specimens.


Journal

Asian Pacific journal of cancer prevention : APJCP
ISSN: 2476-762X
Titre abrégé: Asian Pac J Cancer Prev
Pays: Thailand
ID NLM: 101130625

Informations de publication

Date de publication:
01 Sep 2022
Historique:
received: 08 07 2020
entrez: 29 9 2022
pubmed: 30 9 2022
medline: 1 10 2022
Statut: epublish

Résumé

According to several studies, there is an association between human papillomavirus (HPV) and breast cancer. Therefore, detection and genotyping of HPV seem important. The present study aimed to investigate the presence of HPV DNA in breast tissues  by analyzing the L1 gene. This case-control study was conducted on 63 formalin-fixed paraffin-embedded (FFPE) tissues of invasive ductal carcinoma (IDC) as the case group and 32 FFPE tissues of fibroadenoma as the control group. HPV DNA was detected using the polymerase chain reaction assay. Positive samples were then subjected to genotyping. All statistical analyses were performed in SPSS version 22.0. The patients' age ranged from 15 to 92 years, with a mean age of 43.54±16.36 years. HPV DNA was detected in 17/95 (17.89%) samples, including 9/32 (28.12%) fibroadenoma samples and 8/63 (12.69%) IDC samples. No significant difference was observed regarding the presence of HPV DNA between the IDC and fibroadenoma tissues (P=0.08). However, a significant difference was found in the detection of high-risk HPV (HR-HPV) between the case and control groups (P=0.03). In the case group, 87.5% of the detected viruses (7/8 samples) were HR-HPV, while in the control group, 22.22% of positive samples (2/9 samples) were HR-HPV (P=0.03). Based on the results, HR-HPV and low-risk HPV genotypes were detected in 53% (9/17) and 47% (8/17) of positive samples, respectively. In this study, 12.69% of IDC samples were positive for HPV genomes, and HR-HPV was detected in 87.5% of these samples. The present results suggest the important role of HR-HPV in the development of breast cancer.

Sections du résumé

BACKGROUND BACKGROUND
According to several studies, there is an association between human papillomavirus (HPV) and breast cancer. Therefore, detection and genotyping of HPV seem important. The present study aimed to investigate the presence of HPV DNA in breast tissues  by analyzing the L1 gene.
MATERIALS AND METHODS METHODS
This case-control study was conducted on 63 formalin-fixed paraffin-embedded (FFPE) tissues of invasive ductal carcinoma (IDC) as the case group and 32 FFPE tissues of fibroadenoma as the control group. HPV DNA was detected using the polymerase chain reaction assay. Positive samples were then subjected to genotyping. All statistical analyses were performed in SPSS version 22.0.
RESULTS RESULTS
The patients' age ranged from 15 to 92 years, with a mean age of 43.54±16.36 years. HPV DNA was detected in 17/95 (17.89%) samples, including 9/32 (28.12%) fibroadenoma samples and 8/63 (12.69%) IDC samples. No significant difference was observed regarding the presence of HPV DNA between the IDC and fibroadenoma tissues (P=0.08). However, a significant difference was found in the detection of high-risk HPV (HR-HPV) between the case and control groups (P=0.03). In the case group, 87.5% of the detected viruses (7/8 samples) were HR-HPV, while in the control group, 22.22% of positive samples (2/9 samples) were HR-HPV (P=0.03). Based on the results, HR-HPV and low-risk HPV genotypes were detected in 53% (9/17) and 47% (8/17) of positive samples, respectively.
CONCLUSION CONCLUSIONS
In this study, 12.69% of IDC samples were positive for HPV genomes, and HR-HPV was detected in 87.5% of these samples. The present results suggest the important role of HR-HPV in the development of breast cancer.

Identifiants

pubmed: 36172685
doi: 10.31557/APJCP.2022.23.9.3201
pmc: PMC9810311
pii:
doi:

Substances chimiques

DNA, Viral 0
Formaldehyde 1HG84L3525
DNA 9007-49-2

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3201-3207

Références

Int J Appl Basic Med Res. 2016 Apr-Jun;6(2):84-9
pubmed: 27127735
Breast Cancer Res Treat. 2008 May;109(1):55-8
pubmed: 17624590
Infect Agent Cancer. 2015 Oct 26;10:36
pubmed: 26504492
Clin Microbiol Rev. 2012 Apr;25(2):215-22
pubmed: 22491770
J Int Med Res. 2011;39(5):1636-44
pubmed: 22117964
J Med Virol. 2005 Feb;75(2):276-81
pubmed: 15602723
Clin Microbiol Rev. 2003 Jan;16(1):1-17
pubmed: 12525422
Hum Vaccin Immunother. 2016 Jul 2;12(7):1936-9
pubmed: 27082145
Asian Pac J Cancer Prev. 2016;17(9):4357-4361
pubmed: 27797244
Rev Obstet Gynecol. 2008 Winter;1(1):2-10
pubmed: 18701931
Cancer Res Treat. 2005 Dec;37(6):319-24
pubmed: 19956366
Asian Pac J Cancer Prev. 2015;16(17):7883-7
pubmed: 26625815
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
ScientificWorldJournal. 2012;2012:837191
pubmed: 22566779
Ecancermedicalscience. 2015 Jun 25;9:548
pubmed: 26180547
Virol J. 2012 Nov 06;9:262
pubmed: 23131123
Infect Agent Cancer. 2016 Mar 14;11:14
pubmed: 26981149
Asian Pac J Cancer Prev. 2014;15(9):4061-5
pubmed: 24935597
World J Surg Oncol. 2018 Mar 22;16(1):63
pubmed: 29566711
Breast Dis. 2018;37(4):207-213
pubmed: 30124441
BMC Cancer. 2017 May 8;17(1):320
pubmed: 28482874
J Exp Clin Cancer Res. 2006 Dec;25(4):515-21
pubmed: 17310842
Breast J. 2007 Jul-Aug;13(4):383-91
pubmed: 17593043
Breast. 2013 Aug;22 Suppl 2:S30-7
pubmed: 24074789
J Natl Cancer Inst. 2000 Jul 19;92(14):1126-35
pubmed: 10904085
BMC Cancer. 2011 Jan 20;11:27
pubmed: 21247504
Asian Pac J Cancer Prev. 2018 Nov 29;19(11):3039-3044
pubmed: 30485938
Anticancer Res. 2015 Feb;35(2):851-6
pubmed: 25667466
Breast Cancer Res Treat. 2011 Apr;126(2):515-20
pubmed: 20740311
Asian Pac J Cancer Prev. ;18(7):1839-1845
pubmed: 28749118
Iran J Basic Med Sci. 2016 Mar;19(3):231-7
pubmed: 27114791
Br J Cancer. 2005 Oct 17;93(8):946-8
pubmed: 16222323
Iran J Pathol. 2015 Winter;10(1):41-6
pubmed: 26516324
Sci Rep. 2017 Feb 27;7:43591
pubmed: 28240743
Breast Cancer Res Treat. 1992;21(2):95-100
pubmed: 1320958
Int J Breast Cancer. 2017;2017:2481021
pubmed: 29201466
Br J Cancer. 2009 Oct 20;101(8):1345-50
pubmed: 19724278
Cancers (Basel). 2010 Apr 30;2(2):752-72
pubmed: 24281093
Int J Gynecol Cancer. 2012 Mar;22(3):343-7
pubmed: 22214962
Infect Agent Cancer. 2015 Sep 07;10:29
pubmed: 26347799
Pol J Microbiol. 2018 Mar 9;67(1):73-79
pubmed: 30015427
Breast Cancer Res Treat. 2004 Mar;84(2):131-7
pubmed: 14999143
CA Cancer J Clin. 2013 Jan;63(1):57-81
pubmed: 23258613

Auteurs

Mastaneh Alinezhadi (M)

Cancer Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

Manoochehr Makvandi (M)

Department of Virology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

Gholam Abbas Kaydani (GA)

Department of Laboratory Sciences, School of Allied Health Sciences Ahvaz Jundishapur University of Medical sciences Ahvaz, Iran.

Seyed Nematollah Jazayeri (SN)

Department of Pathology, Imam Khomeini Hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

Javad Charostad (J)

Department of Virology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

Abdolhassan Talaiezadeh Talaeizadeh (AT)

Cancer Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

Kambiz Ahmadi Angali (KA)

Department of Biostatistics and Epidemiology, Faculty of Health, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH